These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Cardiological findings, transfusional regimen, hepatic biopsy and splenectomy in 16 thalassemic patients in the post-pediatric age]. Montaldo PL; Loddo M; Satta L; Multineddu R; Perpignano G; Pintus A; Lixi M; Carcassi U Boll Soc Ital Cardiol; 1979; 24(1):87-91. PubMed ID: 161970 [No Abstract] [Full Text] [Related]
7. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective. Weiner M; Karpatkin M; Hart D; Seaman C; Vora SK; Henry WL; Piomelli S J Pediatr; 1978 Apr; 92(4):653-8. PubMed ID: 633033 [No Abstract] [Full Text] [Related]
8. Quality of life and life expectancy in thalassemic patients with complications. Gabutti V; Piga A; Sacchetti L; Sandri A; Biginelli M; Saracco P; Ferri M Prog Clin Biol Res; 1989; 309():35-41. PubMed ID: 2780748 [No Abstract] [Full Text] [Related]
9. Long-term administration of desferrioxamine in thalassaemia major. Seshadri R; Colebatch JH; Gordon P; Ekert H Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421 [TBL] [Abstract][Full Text] [Related]
10. [Current treatment of Cooley's disease]. Orsini A; Perrimond H; Mattei M Ann Pediatr (Paris); 1985 Nov; 32(9):769-78. PubMed ID: 4091448 [No Abstract] [Full Text] [Related]
11. [Our experience with "supertransfusive" treatment of homozygous beta-thalassemia]. Esposito L; Ferrara M; Ponte G Pediatria (Napoli); 1983; 91(1):27-30. PubMed ID: 6889088 [No Abstract] [Full Text] [Related]
12. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Flynn DM; Hoffbrand AV; Politis D Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017 [No Abstract] [Full Text] [Related]
13. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132 [No Abstract] [Full Text] [Related]
14. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ; Grady RW Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288 [TBL] [Abstract][Full Text] [Related]
15. [Thalassemic cardiopathy: serial echocardiographic evaluation]. Bosi S; Spinolo L; Cavallini B; Guadagni C; Lama A; Santarelli R; Baccini C G Clin Med; 1982 Apr; 63(4):248-54. PubMed ID: 7128980 [No Abstract] [Full Text] [Related]
16. The heart in thalassemia: a comprehensive review. Sahasakul Y; Chithiraphan S J Med Assoc Thai; 1985 Oct; 68(10):517-27. PubMed ID: 3908610 [No Abstract] [Full Text] [Related]
17. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy. Cohen A; Schwartz E Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880 [No Abstract] [Full Text] [Related]
18. [Current treatment of thalassemia major in children]. Lévy G; Bost M Pediatrie; 1980; 35(5):451-5. PubMed ID: 7422454 [No Abstract] [Full Text] [Related]
19. Scoliosis in beta thalassemia. Papageorgiou O; Papanastasiou DA; Beratis NG; Korovessis P; Oikonomopoulos A Pediatrics; 1991 Aug; 88(2):341-5. PubMed ID: 1861937 [No Abstract] [Full Text] [Related]
20. The clinical management of homozygous beta-thalassemia. Cividalli G Haematologica; 1979 Feb; 64(1):1-12. PubMed ID: 109360 [No Abstract] [Full Text] [Related] [Next] [New Search]